In a groundbreaking study published in BMC Cancer, researchers unveil the pivotal role of a circular RNA, circSLC22A3, in suppressing the aggressive invasion and metastatic behavior of esophageal squamous cell carcinoma (ESCC). ESCC remains a formidable challenge in oncology, largely due to its invasive nature and propensity to metastasize early, resulting in poor clinical outcomes worldwide. The study sheds light on the intricate molecular mechanisms whereby circSLC22A3 modulates ESCC progression, revealing dual pathways that could be exploited for therapeutic interventions.
Esophageal squamous cell carcinoma accounts for a significant proportion of esophageal cancer cases globally, with high mortality attributed to its late detection and rapid dissemination. Precision oncology demands a thorough understanding of the molecular underpinnings behind ESCC’s malignancy. Within this context, non-coding RNAs, particularly circular RNAs (circRNAs), have emerged as crucial regulators in cancer biology. Unlike linear RNAs, circRNAs possess a covalently closed loop structure that confers exceptional stability, enabling them to participate in post-transcriptional regulatory networks. However, the exact roles of many circRNAs in esophageal cancer remained elusive until now.
The researchers employed a multifaceted approach combining transcriptome sequencing and quantitative PCR to systematically profile circSLC22A3 expression in ESCC tissues and cell lines. Their findings revealed a pronounced downregulation of circSLC22A3 in cancerous samples compared to normal esophageal tissues. Through rigorous validation techniques including Sanger sequencing, RNase R digestion assays, and fluorescence in situ hybridization, the circular nature and subcellular localization of circSLC22A3 were confirmed, setting the stage for functional characterization.
.adsslot_37WGebTzZ8{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_37WGebTzZ8{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_37WGebTzZ8{ width:320px !important; height:50px !important; } }
ADVERTISEMENT
Functional assays both in vitro and in vivo painted a compelling picture: restoring circSLC22A3 expression notably curtailed the migratory and invasive capacities of ESCC cells, hallmarks of metastatic potential. This suppression of malignant phenotype underscores circSLC22A3’s potential as a tumor suppressor. To dissect the mechanisms underpinning this effect, the team delved into identifying the molecular interactors and regulatory partners of circSLC22A3.
One pathway unveiled involves circSLC22A3 acting as a molecular sponge for miR-19b-3p, a microRNA known previously to facilitate carcinogenic processes. By sequestering miR-19b-3p, circSLC22A3 alleviates its inhibitory control over trafficking kinesin protein 2 (TRAK2), thus promoting TRAK2 expression. TRAK2 plays a crucial role in intracellular transport systems, and its upregulation contributes to limiting cancer cell dissemination. This circSLC22A3/miR-19b-3p/TRAK2 axis delineates a novel molecular cascade impinging directly on ESCC metastatic behavior.
Beyond miRNA sponging, circSLC22A3 exhibits another sophisticated mode of action through RNA-protein interactions. The study identified insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) as a primary circSLC22A3-associated protein. IGF2BP1 is recognized for its role as an m^6A “reader” protein, binding mRNAs modified by N6-methyladenosine, a widespread epigenetic mark influencing mRNA stability and translation. The circSLC22A3/IGF2BP1 interaction perturbs the stabilization of acyl-CoA synthetase bubblegum family member 1 (ACSBG1) mRNA, which bears m^6A modifications.
ACSBG1 has been implicated in lipid metabolism pathways relevant to cancer cell energy dynamics and proliferation. The study’s use of methylated RNA immunoprecipitation sequencing (MeRIP-seq) revealed that IGF2BP1 recognizes m^6A-modified ACSBG1 mRNA, promoting its stability. However, circSLC22A3’s binding to IGF2BP1 appears to disrupt this process, reducing ACSBG1 mRNA half-life as demonstrated by actinomycin D transcriptional shutoff assays. This post-transcriptional control leads to decreased ACSBG1 protein levels, attenuating ESCC invasive properties.
Integrating these molecular insights, the research delineates a dual-axis tumor suppressive mechanism: on one front, the circSLC22A3/miR-19b-3p/TRAK2 axis enhances intracellular trafficking constraints on malignant cells; on the other, the circSLC22A3/IGF2BP1/ACSBG1 axis diminishes pro-metastatic lipid metabolic signaling via targeted mRNA destabilization. The synergy of these pathways orchestrates a robust blockade against tumor progression.
Crucially, tissue microarray analyses underscored clinical relevance by correlating low circSLC22A3 levels with aggressive tumor phenotypes and poor patient prognosis. Such findings elevate circSLC22A3 from a molecular curiosity to a promising biomarker candidate. Furthermore, restoring circSLC22A3 expression or targeting its downstream effectors could inspire novel therapeutic modalities aimed at curbing ESCC metastasis.
This revelation of circSLC22A3’s multifaceted tumor suppressor role invites deeper exploration into circular RNA biology within oncology. The study exemplifies how circRNAs, beyond mere miRNA sponges, engage in intricate RNA-protein interactions modulating epigenetic mRNA modifications, a frontier area in cancer research. The interplay between circRNAs, m^6A machinery, and mRNA stability unveils additional layers of post-transcriptional regulation with therapeutic implications.
Moreover, the identification of TRAK2 as a functional effector through miR-19b-3p modulation links intracellular trafficking pathways to cancer invasiveness, suggesting that targeting motor proteins may offer unexplored anti-metastatic strategies. Similarly, ACSBG1’s involvement bridges metabolic regulation with oncogenic signaling, supporting the growing recognition of metabolic reprogramming in cancer aggressiveness.
As the landscape of ESCC treatment remains bleak with limited targeted options, the discovery of circSLC22A3-mediated signaling axes provides hope for precision medicine approaches. Future research will need to address how circSLC22A3 expression can be modulated clinically and whether synthetic circRNA mimetics or small molecules interfering with miR-19b-3p or IGF2BP1 interactions can be developed.
The study’s comprehensive methodology, integrating transcriptomics, molecular biology, and clinical correlations, sets a benchmark for investigating circRNAs in cancer. This work not only advances esophageal cancer biology but also exemplifies the power of epigenetic and post-transcriptional networks in malignancy.
In summary, circSLC22A3 emerges as a multifaceted suppressor of ESCC invasion and metastasis by concurrently mitigating oncogenic miRNA effects and destabilizing pro-metastatic mRNAs through m^6A-dependent mechanisms. These insights offer fertile ground for novel anti-cancer strategies and underscore the indispensable roles of non-coding RNA species in tumor regulation.
Subject of Research: The role of circSLC22A3 in inhibiting invasion and metastasis in esophageal squamous cell carcinoma via miRNA sponging and m^6A-mediated mRNA regulation.
Article Title: CircSLC22A3 inhibits the invasion and metastasis of ESCC via the miR-19b-3p/TRAK2 axis and by reducing the stability of m^6A-modified ACSBG1 mRNA.
Article References:
Pan, Y., Yang, H., Zhang, J. et al. CircSLC22A3 inhibits the invasion and metastasis of ESCC via the miR-19b-3p/TRAK2 axis and by reducing the stability of m^6A-modified ACSBG1 mRNA. BMC Cancer 25, 971 (2025). https://doi.org/10.1186/s12885-025-14390-8
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14390-8
Tags: cancer biology and molecular mechanismscircSLC22A3 role in esophageal cancercircular RNAs in oncologyESCC metastasis mechanismsesophageal cancer clinical outcomesesophageal squamous cell carcinoma researchm6A pathway in cancernon-coding RNA regulationpost-transcriptional regulation in tumorsprecision oncology strategiestherapeutic targets in ESCCtranscriptome sequencing in cancer studies